Why MacroGenics, Inc.’s (MGNX) Stock Is Down 7.50%
As of Tuesday, July 28, MacroGenics, Inc.’s MGNX share price has dipped by 7.50%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Commentary & Analysis
Why MacroGenics, Inc.’s (MGNX) Stock Is Up 7.16%
As of Monday, July 27, MacroGenics, Inc.’s MGNX share price has surged by 7.16%, which has investors questioning if this is right time to sell.Michael Rose
Why MacroGenics, Inc.’s (MGNX) Stock Is Down 9.35%
As of Friday, July 24, MacroGenics, Inc.’s MGNX share price has dipped by 9.35%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why MacroGenics, Inc.’s (MGNX) Stock Is Down 6.89%
As of Friday, July 10, MacroGenics, Inc.’s MGNX share price has dipped by 6.89%, which has investors questioning if this is right time to buy.Michael Rose
Why MacroGenics, Inc.’s (MGNX) Stock Is Up 5.52%
As of Thursday, July 02, MacroGenics, Inc.’s MGNX share price has surged by 5.52%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | MGNX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $234.5 | $252.6 | 29% |
|
| Shares Out (Mil) | 63.4 | 52.3 | 53% |
|
| Institutional Ownership | 96.1% | 92.1% | 69% |
|
| Float (Mil) | 55.9 | 40.2 | 50% |
|
| Beta | 1.20 | 0.95 | 70% |
|
| Avg Daily Volume (000s) | 762 | 455 | 66% |
|
| Price Change (52-week) |
139.6% | 52.9% | 95% |
|
| Growth | MGNX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 7.3% | 13.6% | 47% |
|
| Net Income (5yr) | 10.5% | (9.9%) | 56% |
|
| EPS (5yr) | 13.7% | 16.0% | 53 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (31.4%) | (15.6%) | 18% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 2 | 3 | |
| Current EPS | $0.258 | $0.035 | ($1.413) | |
| Month Ago EPS | $0.258 | $0.035 | ($1.413) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.570) | ($1.725) | ($1.335) | |
| Year/Year Chg | (144.5%) | (103.0%) | (17.1%) | |
| Financials | MGNX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $157 | $38 | 30% |
|
| Net Income (TTM) (Mil) | ($70) | ($43) | 13% |
|
| EPS (TTM) | ($1.112) | ($1.600) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($70) | ($31) | 7% |
|
| Net Cash Flow (TTM) (Mil) | ($79) | $5 | 15% |
|
| Long-Term Debt (Q1) (Mil) | $31 | $5 | 35% |
|
| Enterprise Value (Q1) (Mil) | $137 | $180 | 23% |
|
| Valuation | MGNX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 11.18 | 2.56 | 91% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | MGNX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (16.2%) | 63.8% | 3% |
|
| Net Margin | (44.8%) | (67.3%) | 12% |
|
| ROA | (31.8%) | (49.8%) | 16% |
|
| ROE | (140.3%) | (55.5%) | 7% |
|
| Liabilities to Assets | 90.3% | 30.3% | 86% |
|
| F-Score | 3 | 3 | 19% |
|
MacroGenics, Inc. did not pass any screens on 7/31/2026.
